Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

Core Viewpoint - The collaboration aims to evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 as a potential treatment for glioblastoma, the most common and aggressive form of brain cancer [1] Group 1: Study Details - The novel combination therapy will be studied as part of the Phase II adaptive platform trial known as the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), sponsored by the Dana-Farber Cancer Institute [1] - This study builds on previously reported positive Phase II results involving INO-5401 in glioblastoma [1] Group 2: Treatment Mechanism - The combination adds a novel, first-in-class PD-1/CTLA-4 bi-specific immunotherapy, which potentially provides additional checkpoint inhibition through CTLA-4 binding [1]